• PDF: Immediate delivery

Global Biosimilars Market - Products, Applications and Regulations

  • Publication Date:November 2012
  • Publisher:Industry Experts
  • Product Type: Report
  • Pages:354

Global Biosimilars Market - Products, Applications and Regulations

Several of the leading 25 manufacturers of biosimilars have been entrenched in the market, and have the experience of marketing products for the last 5-10 years. On the other hand, several companies' position is expected to be challenged over the next ten years, since the rapid growth forecast for the biosimilars market has attracted several new companies to enter this lucrative arena. Current leaders, in order to maintain market share, need to introduce new biosimilars over the next few years with a specific focus on the products in demand. Licensing deals are expected to expand the pipelines of established players, as well as new market entrants.

The global biosimilar market, estimated at US$2 billion in 2012 and expected to touch US$2.7 billion in 2013, is further projected to reach US$19.4 billion by 2018, exhibiting a CAGR of 36.6% over 2009-2018. This growth can be attributed to some of the top-selling biologics coming off-patent over the coming few years and biosimilar manufacturers are bound to make a beeline towards this lucrative opportunity.This report reviews, analyzes and projects the biosimilars market for global and regional markets including the United States, Europe, Asia-Pacific and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and application areas enunciated above. The regional markets further analyzed for 8 more independent countries across Europe - France, Germany, Italy, Spain, the United Kingdom and Rest of Europe; Asia-Pacific - China, India, South Korea and Rest of Asia-Pacific.

The market for application areas of biosimilars analyzed in this study includes Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Others. The report also encompasses the market analysis for product segments - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Others.

This 354 page global market report includes 149 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, application area and product segment.The report covers the brief business profiles of 43 key global players and 54 major players across the United States - 13; Europe - 18; Asia-Pacific - 19 and Rest of World - 4. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of biosimilars. Also enlisting the academic institutions and industry associations engaged in biosimilars, the global list covers the addresses, contact numbers and the website addresses of 168 companies.

  • PART A: GLOBAL MARKET PERSPECTIVE
    • 1. INTRODUCTION
    • 1.1 mAbs - All The Rage In Biosimilars' New Wave
    • 1.2 The Buildup to the Biosimilar Industry
    • 1.3 Current Players: A Sneak Preview
    • 1.3.1 Celltrion
    • 1.3.2 Gedeon Richter
    • 1.3.3 Biocon
    • 1.4 The Big Pharma Industry: Not One to be Left Out
    • 1.4.1 Baxter-Momenta
    • 1.4.2 Merck Serono-Dr. Reddy's Laboratories
    • 1.4.3 Daiichi Sankyo-Coherus Biosciences
    • 1.4.4 Amgen-Watson
    • 1.4.5 Samsung Biologics-Biogen Idec
    • 1.5 On the Flip Side
    • 1.6 The Winner Takes It All
    • 1.7 Product Outline
    • 1.7.1 What are Biosimilars?
    • 1.7.2 The Process of Approval
    • 1.7.3 Backdrop
    • 1.7.4 The Biologics Price Competition and Innovation Act
    • 1.7.4.1 Data Exclusivity
    • 1.7.5 Biosimilars by Product Type
    • 1.7.5.1 Monoclonal Antibodies
    • 1.7.5.1.1 Production Process
    • 1.7.5.2 Erythropoietin
    • 1.7.5.2.1 Functions of EPO
    • 1.7.5.2.2 Mechanism of Action
    • 1.7.5.2.3 Synthesis and Regulation
    • 1.7.5.2.4 Uses in Medicine
    • 1.7.5.3 Human Growth Hormone
    • 1.7.5.3.1 Recombinant Human Growth Hormone
    • 1.7.5.3.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars
    • 1.7.5.4 Insulin
    • 1.7.5.4.1 Biosimilar Insulin
    • 1.7.5.4.2 The Complexity in Producing Biosimilar Insulin
    • 1.7.5.4.3 Biosimilars and the Regulatory Environment Surrounding Them
    • 1.7.5.4.4 The Market for Insulin Biosimilars
    • 1.7.5.5 Granulocyte Colony-Stimulating Factor
    • 1.7.5.5.1 Biological Function
    • 1.7.5.5.2 Genetics
    • 1.7.5.5.3 Use in Therapeutics
    • 1.7.5.6 Interferons
    • 1.7.5.6.1 Interferon Categorization
    • 1.7.5.6.2 Functions of Interferons
    • 1.7.5.6.3 Interferon Alfa
    • 1.7.5.6.4 Interferon Beta-1a
    • 1.7.5.6.5 Interferon Gamma
    • 1.7.5.7 Other Biosimilars
    • 2. BIOSIMILAR APPLICATIONS - A SNAPSHOT
    • 2.1 Blood Disorders
    • 2.2 Chronic and Autoimmune Diseases
    • 2.3 Growth Hormone Deficiency
    • 2.3.1 Growth Hormone Deficiency in Children
    • 2.4 Oncology
    • 2.4.1 Biosimilars in Oncology and Hematology
    • 2.4.2 Biosimilar G-CSF
    • 3. REGULATORY LANDSCAPE
    • 3.1 The United States Food and Drug Administration
    • 3.2 European Medicines Agency
    • 3.3 Other Developments on the Biosimilar Front
    • 3.3.1 The World Health Organization
    • 3.3.2 Canada
    • 3.3.3 Japan
    • 3.3.4 Latin America
    • 3.3.4.1 Argentina
    • 3.3.4.2 Brazil
    • 3.3.4.3 Mexico
    • 3.3.5 India
    • 4. KEY MARKET TRENDS
    • Biosimilars Growth to be Driven by Emerging Markets over the Next Decade
    • Asia Poised to Manufacturing Hub for Biosimilars
    • Biosimilars: Present Perspectives and Future Implications
    • Key Considerations for Biosimilars Development and Commercialization in the US
    • The FDA Guidelines
    • An Assessment of the Current and Future Trends Of Biosimilars in the United States and India
    • Biosimilars: Some Quick Facts
    • The United States Market for Biosimilars
    • The Indian Market for Biosimilars
    • Biosimilars could Drive-Down the Cost of Cancer Treatment
    • FDA Draft Guidance Triggers Evaluation of IP Protection
    • Biosimilar Therapeutics Showing 'Similarity'
    • Key Issues in Biosimilars Commercialization
    • Biosimilars in the US: Regulation, Strategies, and Impact
    • Oncologists Urged to Consider Biosimilars as Cost-Effective Treatment Options
    • Biosimilars Development: Opportunities and Challenges
    • Key Biosimilar Developments During 2011
    • Biosimilars Business Blooming in India
    • Prospects
    • Indian Initiatives
    • Roadblocks Remain
    • Opportunities for Biosimilars in Emerging Markets
    • 5. KEY GLOBAL PLAYERS
    • 3SBio Inc
    • Actavis Group HF.
    • Agilent Technologies, Inc.
    • Amgen, Inc.
    • Astrazeneca Plc
    • Baxter International Inc.
    • Biocon Ltd.
    • Biogen IDEC
    • Bioton S.A.
    • Boehringer Ingelheim GmbH
    • Cadila Healthcare Limited
    • Cangene Corp.
    • Celltrion, Inc.
    • Cipla Ltd.
    • Daiichi Sankyo Company Limited
    • Dong-A Pharmaceutical Co., Ltd
    • Dr. Reddy's Laboratories Ltd.
    • DSM Biologics
    • GE Healthcare Ltd.
    • Glaxosmithkline, Plc
    • Hospira, Inc.
    • iBio, Inc.
    • LG Life Sciences
    • Lonza Group Ltd
    • Medice Arzneimittel Pütter GmbH & Co KG
    • Merck & Co., Inc.
    • Merck KGaA
    • Mitsubishi Tanabe Pharma Corporation
    • Mylan Inc.
    • Novartis AG
    • Perkinelmer, Inc.
    • Pfizer Inc
    • Ranbaxy Laboratories Ltd.
    • Reliance Life Sciences Pvt Ltd
    • Roche Holding AG
    • Samsung Biologics Co Ltd
    • Sandoz International GmbH
    • Sanofi
    • Shantha Biotechnics Ltd
    • Stada Arzneimittel AG
    • Teva Pharmaceutical Industries Ltd.
    • Watson Pharmaceuticals, Inc.
    • Wockhardt Limited
    • 6. KEY BUSINESS TRENDS
    • ProCognia to expand biosimilar collaboration with UniTargeting Research
    • Oncobiologics, Boston Oncology to Commercialize Biosimilar Therapies in MENA region
    • Innovent Biologics Engages Pharmatech Associates for Designing Biosimilars Facility in China
    • Sandoz Initiates Phase-III Trial for Epoetin Alfa
    • AET BioTech, BioXpress Therapeutics Sign Deal for Cancer mAb
    • Reliance Life Sciences Starts Biosimilar Infliximab Trial in India
    • Fujifilm Kyowa Kirin Biologics to Develop Bevacizumab Biosimilar
    • Roche's Rituxan Biosimilar Copies in Market By 2015
    • Asian Biotech Companies to Pioneer Biosimilars for Renal Failure
    • Dr Reddy's Negotiating for Europe Reditux debut
    • FDA approves Teva Cancer Treatment Biosimilar
    • FDA Approves Teva's Tbo-filgrastim Version
    • iBio and GE Healthcare Announce Global Alliance
    • Synthon Strikes Deal for Developing Herceptin Biosimilar
    • Stakeholder Groups Urging FDA to Exempt Plasma Protein Therapy from Biosimilar Pathway
    • Ranbaxy to Commercialize Three Biosimilars by 2015
    • Korean FDA Approves Celltrion's First Monoclonal Antibody
    • Biocon Announces Positive Results for Biosimilar Insulin Glargine Phase I Trial
    • Dr Reddy's to Collaborate with Merck Serono on Biosimilars
    • India Announces New Regulations for Biosimilars
    • Abbott Challenging Provision in Federal Biosimilar Law
    • Amgen Endorses EMA Guidance on Biosimilar mAb
    • Finox Biotech Completes Phase III Trial of Biosimilar r-FSH
    • Court Rules against Merck in Nasonex Patent Infringement Case
    • PlantForm's Biosimilar Trastuzumab Equivalent to Brand Drug In Vivo
    • Daiichi Sankyo, Coherus BioSciences in Biosimilar Deal
    • Amgen, PRA in Biosimilars Deal
    • Pfizer Starts Biosimilar Rituximab Phase I/II trial
    • Daiichi Sankyo, Coherus Biosciences Collaborating to Commercialize Biosimilars
    • EMA Reviewing Biosimilar Version of Infliximab
    • Samsung to Launch Cheaper Biosimilars by 2015
    • Biocon Commences Advanced Research Centre in Bangalore
    • Amgen Seeking Clinical Trial Clarification on Biosimilars
    • Fujifilm, Kyowa in Joint Venture for Humira
    • Dr Reddy's Betting High on Biosimilars
    • GE Healthcare Acquires Xcellerex to Expand Biologicals Offering
    • Celerion, Ricerca in Biosimilar Alliance
    • Biocon and Pfizer Conclude Commercialization Agreement
    • Samsung Biologics and Biogen Idec from Biosimilars Joint Venture
    • Sandoz Initiates Phase III Trials for Filgrastim and Pegfilgrastim
    • Hospira begins US Phase III Trial for Biosimilar EPO
    • Mochida, Fuji Pharma File Biosimilar G-CSF in Japan
    • Transgene Moves rh-EPO Technology to German TSS Export
    • Momenta, Baxter in Biosimilar Alliance
    • Amgen Issued New US Patent on Enbrel
    • Biocon starts R&D Facility in Bio-XCell, Malaysia
    • Dong-A to Establish Biosimilar Plant in Songdo
    • iBio Produces Rituximab in Plants
    • Pharmerging Countries India and China Promising to Rollout Cheaper Biosimilars
    • Boehringer Ingelheim Ventures into Biosimilars
    • Sanofi Announces Fresh Long-Term Objectives
    • Hospira Looks to Biosimilars and Increased use of Generics for Growth
    • Stada, Richter to Collaborate on Biosimilar Development
    • IMS Launches MIDAS Biosimilars
    • Biosmilars Luring Unlikely Partnerships
    • Merck, Hanwha Ink Enbrel Deal
    • Lupin-NeuClone Deal to Develop Oncology Biosimilars
    • Brazil to Manufacture Biosimilar Adalimumab
    • Spectrum, Viropro to Develop Rituximab Biosimilar
    • Sandoz Monitoring Ongoing Biosimilar G-CSF (filgrastim) Study
    • South Korea to Promote Investments in Biosimilars
    • Sandoz Announces Start of Phase II Trial for Biosimilar Rituximab
    • Dr Reddy's Releases Biosimilar Aranesp
    • 7. GLOBAL MARKET OVERVIEW
    • 7.1 Market Overview by Application Area
    • 7.1.1 Biosimilars Application Area Overview by Global Region
    • 7.1.1.1 Blood Disorders
    • 7.1.1.2 Chronic Diseases
    • 7.1.1.3 Growth Hormone Deficiency
    • 7.1.1.4 Oncology
    • 7.1.1.5 Other Biosimilar Applications
    • 7.2 Market Overview by Product Segment
    • 7.2.1 Biosimilars Product Segment Overview by Global Region
    • 7.2.1.1 Biosimilar Monoclonal Antibodies
    • 7.2.1.2 Biosimilar Erythropoietin
    • 7.2.1.3 Biosimilar Human Growth Hormone
    • 7.2.1.4 Biosimilar Insulin
    • 7.2.1.5 Biosimilar G-CSF
    • 7.2.1.6 Biosimilar Interferons
    • 7.2.1.7 Other Biosimilar Products
  • PART B: REGIONAL MARKET PERSPECTIVE
    • REGIONAL MARKET OVERVIEW
    • 1. THE UNITED STATES
    • 1.1 Market Overview by Application Area
    • 1.2 Market Overview by Product Segment
    • 1.3 Major Market Players
    • Agilent Technologies, Inc.
    • Amgen, Inc.
    • Baxter International Inc.
    • Biogen IDEC
    • Dynavax Technologies Corporation
    • Hospira, Inc.
    • iBio, Inc.
    • Merck & Co., Inc.
    • Momenta Pharmaceuticals inc
    • Mylan Inc.
    • Perkinelmer, Inc.
    • Pfizer Inc
    • Watson Pharmaceuticals, Inc.
    • 2. EUROPE
    • 2.1 Current Market Scenario
    • 2.2 Market Overview by Geographic Region
    • 2.3 Market Overview by Application Area
    • 2.3.1 Biosimilars Application Area Overview by European Region
    • 2.3.1.1 Blood Disorders
    • 2.3.1.2 Chronic Diseases
    • 2.3.1.3 Growth Hormone Deficiency
    • 2.3.1.4 Oncology
    • 2.3.1.5 Other Biosimilar Applications
    • 2.4 Market Overview by Product Segment
    • 2.4.1 Biosimilars Product Segment Overview by European Region
    • 2.4.1.1 Biosimilar Monoclonal Antibodies
    • 2.4.1.2 Biosimilar Erythropoietin
    • 2.4.1.3 Biosimilar Human Growth Hormone
    • 2.4.1.4 Biosimilar Insulin
    • 2.4.1.5 Biosimilar G-CSF
    • 2.4.1.6 Biosimilar Interferons
    • 2.4.1.7 Other Biosimilar Products
    • 2.5 Major Market Players
    • Actavis Group HF. (Iceland)
    • Astrazeneca PLC (United Kingdom)
    • BiogEnerix AG (Germany)
    • Biopartners GmbH (Switzerland)
    • Bioton S.A. (Poland)
    • Boehringer Ingelheim GmbH (Germany)
    • DSM Biologics (The Netherlands)
    • GE Healthcare Ltd. (United Kingdom)
    • Glaxosmithkline, PLC (United Kingdom)
    • Hexal AG (Germany)
    • Lonza Group Ltd (Switzerland)
    • Medice Arzneimittel Pütter GmbH & Co Kg (Germany)
    • Merck KGaA (Germany)
    • Novartis AG (Switzerland)
    • Roche Holding AG (Switzerland)
    • Sandoz International GmbH (Germany)
    • Sanofi (France)
    • Stada Arzneimittel AG (Germany)
    • 2.6 European Market Overview by Country
    • 2.6.1 France
    • 2.6.1.1 Market Overview by Application Area
    • 2.6.1.2 Market Overview by Product Segment
    • 2.6.2 Germany
    • 2.6.2.1 Market Overview by Application Area
    • 2.6.2.2 Market Overview by Product Segment
    • 2.6.3 Italy
    • 2.6.3.1 Market Overview by Application Area
    • 2.6.3.2 Market Overview by Product Segment
    • 2.6.4 Spain
    • 2.6.4.1 Market Overview by Application Area
    • 2.6.4.2 Market Overview by Product Segment
    • 2.6.5 United Kingdom
    • 2.6.5.1 Market Overview by Application Area
    • 2.6.5.2 Market Overview by Product Segment
    • 2.6.6 Rest of Europe
    • 2.6.6.1 Market Overview by Application Area
    • 2.6.6.2 Market Overview by Product Segment
    • 3. ASIA-PACIFIC
    • 3.1 Market Overview by Geographic Region
    • 3.2 Market Overview by Application Area
    • 3.2.1 Biosimilars Application Area Overview by Asia-Pacific Region
    • 3.2.1.1 Blood Disorders
    • 3.2.1.2 Chronic Diseases
    • 3.2.1.3 Growth Hormone Deficiency
    • 3.2.1.4 Oncology
    • 3.2.1.5 Other Biosimilar Applications
    • 3.3 Market Overview by Product Segment
    • 3.3.1 Biosimilars Product Segment Overview by Asia-Pacific Region
    • 3.3.1.1 Biosimilar Monoclonal Antibodies
    • 3.3.1.2 Biosimilar Erythropoietin
    • 3.3.1.3 Biosimilar Human Growth Hormone
    • 3.3.1.4 Biosimilar Insulin
    • 3.3.1.5 Biosimilar G-CSF
    • 3.3.1.6 Biosimilar Interferons
    • 3.3.1.7 Other Biosimilar Products
    • 3.4 Major Market Players
    • 3SBio Inc (China)
    • Anhui Anke Biotechnology (Group) Co., Ltd. (China)
    • Bharat Biotech International Limited (India)
    • Biocon Ltd. (India)
    • Cadila Healthcare Limited (India)
    • Celltrion, Inc. (South Korea)
    • Cipla Ltd. (India)
    • Claris Lifesciences Limited (India)
    • Daiichi Sankyo Company Limited (Japan)
    • Dong-A Pharmaceutical Co., Ltd (South Korea)
    • Dr. Reddy's Laboratories Ltd. (India)
    • Intas Biopharmaceuticals Ltd. (India)
    • LG Life Sciences (South Korea)
    • Mitsubishi Tanabe Pharma Corporation (Japan)
    • Ranbaxy Laboratories Ltd. (India)
    • Reliance Life Sciences Pvt Ltd (India)
    • Samsung Biologics Co Ltd (South Korea)
    • Shantha Biotechnics Ltd (India)
    • Wockhardt Limited (India)
    • 3.5 Asia-Pacific Market Overview by Country
    • 3.5.1 China
    • 3.5.1.1 Current Market Scenario
    • 3.5.1.2 Market Overview by Application Area
    • 3.5.1.3 Market Overview by Product Segment
    • 3.5.2 India
    • 3.5.2.1 Current Market Scenario
    • 3.5.2.2 Market Overview by Application Area
    • 3.5.2.3 Market Overview by Product Segment
    • 3.5.3 South Korea
    • 3.5.3.1 Current Market Scenario
    • 3.5.3.2 Market Overview by Application Area
    • 3.5.3.3 Market Overview by Product Segment
    • 3.5.4 Rest of Asia-Pacific
    • 3.5.4.1 Market Overview by Application Area
    • 3.5.4.2 Market Overview by Product Segment
    • 4. REST OF WORLD
    • 4.1 Market Overview by Application Area
    • 4.2 Market Overview by Product Segment
    • 4.3 Major Market Players
    • Bioclones (Pty) Ltd. (South Africa)
    • Cangene Corp. (Canada)
    • Medicago Inc. (Canada)
    • Teva Pharmaceutical Industries Ltd. (Israel)
  • PART C: GUIDE TO THE INDUSTRY
    • 1. NORTH AMERICA
    • 1.1 Canada
    • 1.2 United States
    • 2. EUROPE
    • 2.1 France
    • 2.2 Germany
    • 2.3 Hungary
    • 2.4 Iceland
    • 2.5 Ireland
    • 2.6 Lithuania
    • 2.7 Malta
    • 2.8 Poland
    • 2.9 Russia
    • 2.10 Spain
    • 2.11 Switzerland
    • 2.12 The Netherlands
    • 2.13 United Kingdom
    • 3. ASIA-PACIFIC
    • 3.1 Australia
    • 3.2 China
    • 3.3 India
    • 3.4 Japan
    • 3.5 Singapore
    • 3.6 South Korea
    • 3.7 Taiwan
    • 3.8 Vietnam
    • 4. REST OF WORLD
    • 4.1 Brazil
    • 4.2 Iran
    • 4.3 Israel
    • 4.4 Mexico
    • 4.5 South Africa
  • PART D: ANNEXURE
    • 1. RESEARCH METHODOLOGY
    • 2. THE QUESTIONNAIRE
    • 3. FEEDBACK
  • Charts & Graphs
  • PART A: GLOBAL MARKET PERSPECTIVE
    • Chart 1: The Leading mAbs and Years of Patent Expiry in United States and Europe
    • Chart 2: The Biosimilar Manufacturers with Most No. of mAbs in Pipeline
    • Chart 3: The Global Top-5 Biosimilar Manufacturers by Market Shares (%) for 2011 & 2012
    • Chart 4: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Blood Disorders by Geographic Region
    • Chart 5: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Chronic Diseases by Geographic Region
    • Chart 6: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Growth Hormone Deficiencies by Geographic Region
    • Chart 7: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Oncology by Geographic Region
    • Chart 8: A Comparative Study on Biosimilars Between The Approaches of The European Union and The United States
    • Chart 9: The Innovator Products and their Corresponding Biosimilars by Company
    • Chart 10: Global Biosimilars Market Analysis (2009-2018) in USD Million
    • Chart 11: Global Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 12: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 13: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 14: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 15: Global Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 16: Glance at 2009, 2013 and 2018 Global Chronic Diseases Market Share (%) of Biosimilars by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 17: Global Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 18: Glance at 2009, 2013 and 2018 Global Growth Hormone Deficiency Market Share (%) of Biosimilars by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 19: Global Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 20: Glance at 2009, 2013 and 2018 Global Oncology Market Share (%) of Biosimilars by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 21: Global Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 22: Glance at 2009, 2013 and 2018 Global Other Biosimilar Applications Market Share (%) of Biosimilars by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 23: Global Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 24: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Chart 25: Global Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 26: Glance at 2009, 2013 and 2018 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 27: Global Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 28: Glance at 2009, 2013 and 2018 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 29: Global Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 30: Glance at 2009, 2013 and 2018 Global Biosimilar Human Growth Hormone Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 31: Global Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 32: Glance at 2009, 2013 and 2018 Global Biosimilar Insulin Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 33: Global Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 34: Glance at 2009, 2013 and 2018 Global Biosimilar G-CSF Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 35: Global Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 36: Glance at 2009, 2013 and 2018 Global Biosimilar Interferons Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • Chart 37: Global Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 38: Glance at 2009, 2013 and 2018 Global Other Biosimilar Products Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
  • PART B: REGIONAL MARKET PERSPECTIVE
    • Chart 39: The Projection of Largest Regions in terms of Market Growth (2009-2018) for Biosimilars by Geography - United States, Europe and Asia-Pacific
    • Chart 40: Global Biosimilars Market Analysis (2009-2018) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World in USD Million
    • Chart 41: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Geographic Region - United States, Europe, Asia-Pacific and Rest of World
    • THE UNITED STATES
    • Chart 42: United States Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 43: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 44: United States Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 45: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • EUROPE
    • Chart 46: European Biosimilars Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 47: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 48: European Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 49: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 50: European Biosimilars Market Analysis (2009-2018) for Application in Blood Disorders by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 51: Glance at 2009, 2013 and 2018 European Blood Disorders Market Share (%) of Biosimilars by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 52: European Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 53: Glance at 2009, 2013 and 2018 European Chronic Diseases Market Share (%) of Biosimilars by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 54: European Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 55: Glance at 2009, 2013 and 2018 European Growth Hormone Deficiency Market Share (%) of Biosimilars by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 56: European Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 57: Glance at 2009, 2013 and 2018 European Oncology Market Share (%) of Biosimilars by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 58: European Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 59: Glance at 2009, 2013 and 2018 European Other Biosimilar Applications Market Share (%) of Biosimilars by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 60: European Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 61: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Chart 62: European Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 63: Glance at 2009, 2013 and 2018 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 64: European Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 65: Glance at 2009, 2013 and 2018 European Biosimilar Erythropoietin Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 66: European Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 67: Glance at 2009, 2013 and 2018 European Biosimilar Human Growth Hormone Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 68: European Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 69: Glance at 2009, 2013 and 2018 European Biosimilar Insulin Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 70: European Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 71: Glance at 2009, 2013 and 2018 European Biosimilar G-CSF Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 72: European Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 73: Glance at 2009, 2013 and 2018 European Biosimilar Interferons Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • Chart 74: European Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
    • Chart 75: Glance at 2009, 2013 and 2018 European Other Biosimilar Products Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
    • France
    • Chart 76: French Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 77: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 78: French Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 79: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Germany
    • Chart 80: German Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 81: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 82: German Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 83: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Italy
    • Chart 84: Italian Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 85: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 86: Italian Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 87: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Spain
    • Chart 88: Spanish Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 89: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 90: Spanish Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 91: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • United Kingdom
    • Chart 92: United Kingdom Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 93: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 94: United Kingdom Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 95: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Rest of Europe
    • Chart 96: Rest of Europe Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 97: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 98: Rest of Europe Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 99: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • ASIA-PACIFIC
    • Chart 100: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 101: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 102: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 103: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 104: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Blood Disorders by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 105: Glance at 2009, 2013 and 2018 Asia-Pacific Blood Disorders Market Share (%) of Biosimilars by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 106: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 107: Glance at 2009, 2013 and 2018 Asia-Pacific Chronic Diseases Market Share (%) of Biosimilars by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 108: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 109: Glance at 2009, 2013 and 2018 Asia-Pacific Growth Hormone Deficiency Market Share (%) of Biosimilars by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 110: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 111: Glance at 2009, 2013 and 2018 Asia-Pacific Oncology Market Share (%) of Biosimilars by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 112: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 113: Glance at 2009, 2013 and 2018 Asia-Pacific Other Biosimilar Applications Market Share (%) of Biosimilars by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 114: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 115: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Chart 116: Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 117: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 118: Asia-Pacific Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 119: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Erythropoietin Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 120: Asia-Pacific Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 121: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Human Growth Hormone Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 122: Asia-Pacific Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 123: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Insulin Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 124: Asia-Pacific Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 125: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar G-CSF Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 126: Asia-Pacific Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 127: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Interferons Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • Chart 128: Asia-Pacific Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific in USD Million
    • Chart 129: Glance at 2009, 2013 and 2018 Asia-Pacific Other Biosimilar Products Market Share (%) by Geographic Region - China, India, South Korea and Rest of Asia-Pacific
    • China
    • Chart 130: Chinese Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 131: Glance at 2009, 2013 and 2018 Chinese Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 132: Chinese Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 133: Glance at 2009, 2013 and 2018 Chinese Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • India
    • Chart 134: Indian Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 135: Glance at 2009, 2013 and 2018 Indian Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 136: Indian Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 137: Glance at 2009, 2013 and 2018 Indian Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • South Korea
    • Chart 138: Korean Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 139: Glance at 2009, 2013 and 2018 Korean Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 140: Korean Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 141: Glance at 2009, 2013 and 2018 Korean Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • Rest of Asia-Pacific
    • Chart 142: Rest of Asia-Pacific Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 143: Glance at 2009, 2013 and 2018 Rest of Asia-Pacific Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 144: Rest of Asia-Pacific Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 145: Glance at 2009, 2013 and 2018 Rest of Asia-Pacific Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
    • REST OF WORLD
    • Chart 146: Rest of World Biosimilars Market Analysis (2009-2018) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
    • Chart 147: Glance at 2009, 2013 and 2018 Rest of World Biosimilars Market Share (%) by Application Area - Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
    • Chart 148: Rest of World Biosimilars Market Analysis (2009-2018) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
    • Chart 149: Glance at 2009, 2013 and 2018 Rest of World Biosimilars Market Share (%) by Product Segment - Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
+44 20 8816 8548

Ask a question about Global Biosimilars Market - Products, Applications and Regulations

Enter the characters you see in the picture below
Captcha